Stock Track | Krystal Biotech Soars 5.25% in Pre-Market on Strong Q1 Earnings and FDA RMAT Designation

Stock Track

May 04

Krystal Biotech Inc. (KRYS) experienced a significant pre-market surge of 5.25% on Monday, driven by the release of robust first-quarter financial results and a recent positive regulatory development for its oncology pipeline.

The company announced its Q1 2026 financial and operating results pre-market, reporting product revenue of USD 116.357 million and net income of USD 55.932 million. These strong figures indicate healthy commercial execution and profitability, providing a fundamental catalyst for the stock's upward movement.

Additionally, investor sentiment was bolstered by news that the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, Krystal Biotech's redosable HSV-based immunotherapy for advanced or metastatic non-small cell lung cancer. This regulatory status, announced prior to the earnings, provides the drug candidate with enhanced FDA guidance and potential for accelerated review, elevating the profile of the company's emerging oncology franchise.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1154674386"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154674386\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154674386?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154674386","market":"nz","top_or_hot":-1,"title":"Stock Track | Krystal Biotech Soars 5.25% in Pre-Market on Strong Q1 Earnings and FDA RMAT Designation","media":"Stock Track","content":"<p>Krystal Biotech Inc. (KRYS) experienced a significant pre-market surge of 5.25% on Monday, driven by the release of robust first-quarter financial results and a recent positive regulatory development for its oncology pipeline.</p><p>The company announced its Q1 2026 financial and operating results pre-market, reporting product revenue of USD 116.357 million and net income of USD 55.932 million. These strong figures indicate healthy commercial execution and profitability, providing a fundamental catalyst for the stock's upward movement.</p><p>Additionally, investor sentiment was bolstered by news that the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, Krystal Biotech's redosable HSV-based immunotherapy for advanced or metastatic non-small cell lung cancer. This regulatory status, announced prior to the earnings, provides the drug candidate with enhanced FDA guidance and potential for accelerated review, elevating the profile of the company's emerging oncology franchise.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Krystal Biotech Soars 5.25% in Pre-Market on Strong Q1 Earnings and FDA RMAT Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Krystal Biotech Soars 5.25% in Pre-Market on Strong Q1 Earnings and FDA RMAT Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-04 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Krystal Biotech Inc. (KRYS) experienced a significant pre-market surge of 5.25% on Monday, driven by the release of robust first-quarter financial results and a recent positive regulatory development for its oncology pipeline.</p><p>The company announced its Q1 2026 financial and operating results pre-market, reporting product revenue of USD 116.357 million and net income of USD 55.932 million. These strong figures indicate healthy commercial execution and profitability, providing a fundamental catalyst for the stock's upward movement.</p><p>Additionally, investor sentiment was bolstered by news that the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, Krystal Biotech's redosable HSV-based immunotherapy for advanced or metastatic non-small cell lung cancer. This regulatory status, announced prior to the earnings, provides the drug candidate with enhanced FDA guidance and potential for accelerated review, elevating the profile of the company's emerging oncology franchise.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRYS","symbol_name":"Krystal Biotech Inc.","start_time":0,"source_url":"","article_id":"1154674386","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154674386","pubTimestamp":1777892567,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Krystal Biotech Inc. (KRYS) experienced a significant pre-market surge of 5.25% on Monday, driven by the release of robust first-quarter financial results and a recent positive regulatory development...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRYS":"Krystal Biotech Inc."},"translate_title":"个股追踪|Krystal Biotech盘前飙升5.25%，因Q1盈利强劲和FDA RMAT指定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1},"content_text":"Krystal Biotech Inc. (KRYS) experienced a significant pre-market surge of 5.25% on Monday, driven by the release of robust first-quarter financial results and a recent positive regulatory development for its oncology pipeline.The company announced its Q1 2026 financial and operating results pre-market, reporting product revenue of USD 116.357 million and net income of USD 55.932 million. These strong figures indicate healthy commercial execution and profitability, providing a fundamental catalyst for the stock's upward movement.Additionally, investor sentiment was bolstered by news that the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, Krystal Biotech's redosable HSV-based immunotherapy for advanced or metastatic non-small cell lung cancer. This regulatory status, announced prior to the earnings, provides the drug candidate with enhanced FDA guidance and potential for accelerated review, elevating the profile of the company's emerging oncology franchise.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}